Max Colao, OncoVerity CEO
Tiny multiomics biotech secures former J&J drug, new execs and new financing
A new spinout from Belgium’s argenx seeks to give new life to a candidate once in-licensed to J&J.
OncoVerity announced Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.